Diagnosing all types lymphomas
Our research, pioneered by the late Professor David Mason, developed an accurate and efficient way of diagnosing all the different types of non-Hodgkin lymphomas. This technology uses antibodies, specific to marker molecules on the surface of lymphoma cells, to identify each patient’s specific types of lymphoma. Better diagnosis means that patients receive better treatments.
The Leukaemia & Lymphoma Research Immunodiagnostics facility is now a commercial enterprise based in Oxford that produces hundreds of antibodies to scientists across the UK ensuring all lymphoma patients are accurately diagnosed.
This facility, which is now known as OxFabs continues to generate revenue for Leukaemia & Lymphoma Research’s vital research. Find out more at www.oxfabs.com
Diagnosing myeloproliferative neoplasm
Our researchers were among the first in the world to discover a mutation in a gene, called JAK2 that is present in most patients with a myeloproliferative neoplasm (MPN).
The discovery of this gene has made it easier to diagnose this group of blood disorders and is laying the foundations for the development of new treatments.
Detecting chronic lymphocytic leukaemia early
Our scientists were the first to show that some blood cancers are being detected too early. Research showed that many people have chronic lymphocytic leukaemia (CLL) like cells in their blood, but no other symptoms of this blood cancer. This research is helping to improve diagnosis and treatment for this variable form of blood cancer.
Virus link to Hodgkin lymphoma
Our researchers were among the first to identify the link between a common virus called Epstein Barr virus (EBV) and Hodgkin lymphoma.
Research now suggests that each person’s genetic make-up is important in determining how they will react to infection with EBV, and whether they will go on to develop Hodgkin lymphoma. Clarifying these links is helping to develop better treatments and possibly even preventing this blood cancer all together.